Core Insights - Harvard Bioscience, Inc. has appointed John Duke to its board of directors, effective June 2, 2025, and he will also serve on the audit and nominating and governance committees [1][2] - Katherine Eade has been named Lead Independent Director of the Company's board of directors [1] - Thomas Loewald has retired from the board after serving since October 2017 [3] Company Overview - Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical development [4] - The Company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical and biotechnology organizations, with operations in the United States, Europe, and China [4]
Harvard Bioscience Appoints John Duke to Board of Directors